Related coverage linked through entity extraction aliases.
Aug 06, 2026
A randomized trial shows self-acupressure reduces fatigue and improves quality of life in ovarian cancer; a systematic review finds light to moderate massage safe for cancer patients.
May 05, 2026
TuHURA Biosciences filed an FDA IND for TBS-2025, a VISTA-targeting antibody, plus a menin inhibitor in mutNPM1 r/r AML. Phase 2 targets early Q2 2026 with preliminary Stage 1 results in Q3 2026.
Aug 07, 2026
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
Jul 31, 2026
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Jun 02, 2026
AI-driven studies are advancing cancer drug discovery across multiple tumor types, including a pan-cancer proposal of AMG-900, a novel gp130 inhibitor for colorectal cancer, and the Kinic Index for hepatocellular carcinoma. Machine learning is also being integrated into computational platforms like Isomorphic Labs' IsoDDE to model molecular interactions.
Aug 03, 2026
Dosing has begun in a Phase 1 trial of ZI-MA4-1, the first MAGE-A4-targeting TCR-NK cell therapy for solid tumours, with initial data expected from mid-2026. The off-the-shelf therapy is being evaluated at two UK sites.
Aug 01, 2026
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
Jul 30, 2026
A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.
Jul 24, 2026
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
Jun 21, 2026
In Australia, 19 women are diagnosed daily with gynaecological cancer, and experts say late detection is the primary issue. Ovarian cancer is often caught at advanced stages, while endometrial cancer deaths are rising. Personal stories underscore the need for early symptom awareness.
Jun 19, 2026
Allarity Therapeutics will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026 on its Phase 2 ovarian cancer trial of stenoparib. The company also dosed first patients in February 2026 in a VA-funded Phase 2 trial of stenoparib plus temozolomide for relapsed small cell lung cancer.
Jun 18, 2026
A breakthrough ovarian cancer drug, mirvetuximab soravtansine, is now available on the NHS, offering extended survival and improved quality of life. The 'biological missile' therapy targets cancer cells directly, reducing side-effects compared to standard chemotherapy. Up to 400 patients in England could benefit each year.
Jun 11, 2026
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
Jun 02, 2026
Compugen reported a Q1 2026 net loss of $7.7 million with approximately $134.9 million in cash, expecting runway into 2029. The COM701 MAIA-ovarian trial is enrolling across the U.S., Israel, and France, with interim analysis expected by Q1 2027. Partner AstraZeneca is advancing rilvegostomig across 11 Phase 3 trials.
Jun 02, 2026
Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.
May 30, 2026
The phase 3 ROSELLA trial showed relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer by 4.1 months versus nab-paclitaxel alone. The benefit was consistent across all subgroups regardless of prior taxane exposure, leading to FDA approval in March 2026. The combination also met its progression-free survival endpoint and demonstrated a favorable safety profile.
May 23, 2026
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
May 07, 2026
Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
May 02, 2026
A Pennsylvania jury ordered Johnson & Johnson to pay $250,000 to the family of Gayle Emerson in a talc baby powder ovarian cancer case. The verdict comes amid more than 90,000 talc lawsuits and ongoing fights over expert testimony.
Apr 28, 2026
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
